Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels.
Emicizumab mimics the hemostatic activity of activated factor VIII (FVIIIa) within the tenase complex. Despite functional similarities between FVIIIa and emicizumab, conventional laboratory methods designed for monitoring of FVIII activity are inappropriate for the measurement of emicizumab. At pres...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0271330 |
| _version_ | 1811223099412054016 |
|---|---|
| author | Nasim Shahidi Hamedani Johannes Oldenburg Bernd Pötzsch Jens Müller |
| author_facet | Nasim Shahidi Hamedani Johannes Oldenburg Bernd Pötzsch Jens Müller |
| author_sort | Nasim Shahidi Hamedani |
| collection | DOAJ |
| description | Emicizumab mimics the hemostatic activity of activated factor VIII (FVIIIa) within the tenase complex. Despite functional similarities between FVIIIa and emicizumab, conventional laboratory methods designed for monitoring of FVIII activity are inappropriate for the measurement of emicizumab. At present, a modified one stage (FVIII) assay (mOSA) is mainly used for emicizumab monitoring. Two-stage chromogenic FVIII assays based on human factors can be used, although limited performance due to lack of corresponding optimization might be observed. Furthermore, the presence of FVIII or anticoagulants in the patient sample may falsify assay results. To address these issues, we optimized and evaluated a two-stage chromogenic assay (emi-tenase) for measurement of emicizumab in plasma samples. Heat inactivation of samples was established to abolish the influence of endogenous or substituted FVIII. The lower limit of quantification (LLoQ) was found to be 2 μg/ml in a manual assay format and 9.5 μg/ml on an automated coagulation analyzer. Intra- and inter-assay coefficients of variation (CV) did not exceed 20%. Analysis of 17 patient plasma samples with severe haemophilia A under emicizumab treatment showed good correlation of results between the emi-tenase assay and the mOSA (Cohens Kappa coefficient = 0.9). Taken together, the emi-tenase assay allows specific measurement of emicizumab plasma levels over a broad concentration range (10 μg/ml to 100 μg/ml). The assay can be applied on an automated coagulation analyzer, demonstrating its applicability within a routine laboratory setting. |
| first_indexed | 2024-04-12T08:26:12Z |
| format | Article |
| id | doaj.art-27951d9540954b22bef2abe0cf16a06d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T08:26:12Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-27951d9540954b22bef2abe0cf16a06d2022-12-22T03:40:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01177e027133010.1371/journal.pone.0271330Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels.Nasim Shahidi HamedaniJohannes OldenburgBernd PötzschJens MüllerEmicizumab mimics the hemostatic activity of activated factor VIII (FVIIIa) within the tenase complex. Despite functional similarities between FVIIIa and emicizumab, conventional laboratory methods designed for monitoring of FVIII activity are inappropriate for the measurement of emicizumab. At present, a modified one stage (FVIII) assay (mOSA) is mainly used for emicizumab monitoring. Two-stage chromogenic FVIII assays based on human factors can be used, although limited performance due to lack of corresponding optimization might be observed. Furthermore, the presence of FVIII or anticoagulants in the patient sample may falsify assay results. To address these issues, we optimized and evaluated a two-stage chromogenic assay (emi-tenase) for measurement of emicizumab in plasma samples. Heat inactivation of samples was established to abolish the influence of endogenous or substituted FVIII. The lower limit of quantification (LLoQ) was found to be 2 μg/ml in a manual assay format and 9.5 μg/ml on an automated coagulation analyzer. Intra- and inter-assay coefficients of variation (CV) did not exceed 20%. Analysis of 17 patient plasma samples with severe haemophilia A under emicizumab treatment showed good correlation of results between the emi-tenase assay and the mOSA (Cohens Kappa coefficient = 0.9). Taken together, the emi-tenase assay allows specific measurement of emicizumab plasma levels over a broad concentration range (10 μg/ml to 100 μg/ml). The assay can be applied on an automated coagulation analyzer, demonstrating its applicability within a routine laboratory setting.https://doi.org/10.1371/journal.pone.0271330 |
| spellingShingle | Nasim Shahidi Hamedani Johannes Oldenburg Bernd Pötzsch Jens Müller Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels. PLoS ONE |
| title | Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels. |
| title_full | Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels. |
| title_fullStr | Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels. |
| title_full_unstemmed | Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels. |
| title_short | Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels. |
| title_sort | optimization and evaluation of a two stage chromogenic assay procedure for measurement of emicizumab plasma levels |
| url | https://doi.org/10.1371/journal.pone.0271330 |
| work_keys_str_mv | AT nasimshahidihamedani optimizationandevaluationofatwostagechromogenicassayprocedureformeasurementofemicizumabplasmalevels AT johannesoldenburg optimizationandevaluationofatwostagechromogenicassayprocedureformeasurementofemicizumabplasmalevels AT berndpotzsch optimizationandevaluationofatwostagechromogenicassayprocedureformeasurementofemicizumabplasmalevels AT jensmuller optimizationandevaluationofatwostagechromogenicassayprocedureformeasurementofemicizumabplasmalevels |